DEF: Zenas BioPharma Sets 2026 Annual Meeting Agenda

Zenas BioPharma, Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on May 11, 2026, to elect directors and ratify its independent auditor.

Summary

• Zenas BioPharma, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on Monday, May 11, 2026, at 8:00 a.m. Eastern Time.
• Stockholders will vote on two key proposals: the election of two Class II director nominees (James Boylan and Patrick Enright) to serve until the 2029 Annual Meeting, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026.
• The board of directors recommends voting "FOR" both proposals.
• The Record Date for voting eligibility is March 12, 2026, with 57,371,044 shares of common stock issued and outstanding.
• Tomas Kiselak, an existing Class II director, will not stand for reelection, and the board size will be reduced by one to eight directors following the meeting.
• The company disclosed executive compensation for 2025 and 2024, with CEO Leon O. Moulder, Jr.'s total compensation at $4,661,000 in 2025 and $19,998,016 in 2024.
• Significant related party transactions include a 2025 PIPE financing that raised $111.8 million in net proceeds, a license agreement with InnoCare Pharma Inc. involving $35.0 million cash and 5,000,000 shares upfront, and a Series C Preferred Stock financing in May 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, administrative filing primarily focused on corporate governance and upcoming stockholder votes, with no direct positive or negative operational or financial news.

Positives

• The company maintains robust corporate governance practices, including a Code of Business Conduct and Ethics, Clawback Policy, Insider Trading Policy, and Anti-Hedging Policy.
• The board of directors has a diverse committee structure (Audit, Compensation, Nominating & Corporate Governance, Science & Technology) with clear responsibilities for risk oversight.
• The company successfully completed a PIPE financing in October 2025, raising $111.8 million in net proceeds, indicating investor confidence.
• The license agreement with InnoCare Pharma Inc. expands the company's pipeline with exclusive rights to orelabrutinib (MS field worldwide, non-oncology outside Greater China/Southeast Asia), ZB021, and ZB022, demonstrating strategic growth.
• The company established a 401(k) matching program effective January 1, 2025, matching 100% of the first 4% of employee contributions, which can aid in employee retention.

Risks

• Forward-looking statements are subject to known and unknown risks, uncertainties, and assumptions, including those described in the company's most recent Annual Report on Form 10-K.
• Risks related to accounting matters, financial reporting, legal and regulatory matters, and cybersecurity are overseen by the Audit Committee.
• Risks relating to executive compensation plans, programs, and arrangements are overseen by the Compensation Committee.
• Risks associated with the independence of the board of directors and potential conflicts of interest are overseen by the Nominating and Corporate Governance Committee.
• Risks related to innovation, new product development, and research and development are overseen by the Science and Technology Committee.

Future Outlook

The filing contains standard forward-looking statements disclosure, noting that all statements other than historical facts are subject to known and unknown risks, uncertainties, and assumptions. It does not provide specific financial guidance or strategic projections for the future.

Management Comments

• "Whether or not you expect to participate in the virtual Annual Meeting, please vote as promptly as possible by Internet, by telephone or, if you received written proxy materials, by signing, dating and returning a proxy card included in these materials, in order to ensure your representation at the Annual Meeting."

Industry Context

StockSavvy.ai notes that Zenas BioPharma operates within the highly competitive and capital-intensive biopharmaceutical industry. The company's strategic moves, such as the licensing agreement with InnoCare for multiple sclerosis and other non-oncology indications, reflect a common industry trend of expanding pipelines through partnerships to diversify risk and leverage external innovation. The involvement of venture capital firms and investment banking professionals on the board, as well as the reliance on equity financing (PIPE, Series C), is typical for a growth-stage biotech company focused on R&D.

Comparison to Industry Standards

• The company's executive compensation program is advised by Alpine Rewards, LLC, which provides "experiential guidance on what is considered fair and competitive practice in our industry," suggesting an alignment with industry benchmarks.
• The board's composition includes directors with extensive experience from other public and private biopharmaceutical companies, such as Leon O. Moulder, Jr. (co-founder of TESARO, Inc., board member of Zai Lab Ltd., previously Trevena, Inc., Dianthus), Hongbo Lu, Ph.D. (previously Vivo Capital, Lilly Asia Ventures, OrbiMed Advisors, board member of Arrowhead Pharmaceuticals, previously Turning Point Therapeutics, Inc., Crown Bioscience Inc., Avedro Inc., Terns Pharmaceuticals Inc.), James Boylan (CEO of Enavate Sciences Inc., board member of Immunome Therapeutics Inc., Compass Therapeutics, Inc., previously CAMP4 Therapeutics Corp.), Patrick Enright (co-founder of Longitude Capital, board member of Veradermics, Incorporated, BioAge Labs, Inc., Jazz Pharmaceuticals PLC, Vera Therapeutics, Inc., previously Aimmune Therapeutics, Inc., Corcept Therapeutics Inc., Vaxcyte, Inc.), Patricia Allen (CFO of Vividion Therapeutics, Inc., Zafgen, Inc., Alnylam Pharmaceuticals, Inc., board member of Deciphera Pharmaceuticals, Inc., Yumanity Therapeutics, Inc.), Jake Nunn (Partner at SR One Capital Management, LP, previously New Enterprise Associates, MPM Capital, L.P., board member of Addex Therapeutics Ltd., previously Regulus Therapeutics Inc., Trevena, Inc., Dermira, Inc., Hyperion Therapeutics, Inc., Hexima Limited, Oventus Medical Ltd.), and John Orloff, M.D. (Venture Partner at Agent Capital LLC, previously Alexion Pharmaceuticals Inc., Baxalta Inc., Merck Serono, Novartis AG, Merck Research Laboratories, board member of BenevolentAI Ltd.). This broad experience across numerous comparable biotech and pharma entities suggests a board structure consistent with industry best practices for governance and strategic oversight.

Management Changes

Corporate Governance

Related Party Transactions

• In October 2025, the company conducted a PIPE financing where entities affiliated with FMR Group, New Enterprise Associates, Fairmount Healthcare Fund II L.P., NextBio, Zebra Aggregator, L.P., SR One, Longitude Venture Partners, IV L.P., and the Leon O. Moulder, Jr. Revocable Trust, along with director Patrick Enright, purchased common stock for an aggregate of $111.8 million net proceeds.
• In October 2025, the company entered into a License Agreement with InnoCare Pharma Inc., a 5% stockholder, granting exclusive rights to certain compounds (orelabrutinib, ZB021, ZB022) in exchange for $35.0 million cash and 5,000,000 shares upfront, with potential future milestone payments up to $723.0 million for orelabrutinib and $656.0 million for preclinical compounds, plus royalties.
• In May 2024, the company completed a Series C Preferred Stock financing where entities affiliated with SR One Capital Management, LP, Delos Capital Fund III, LP, Bristol-Myers Squibb, New Enterprise Associates, Norwest Venture Partners XVI, LP, Enavate Sciences, Longitude Capital, and Fairmount Funds Management LLC purchased Series C Preferred Stock.
• The company is party to a Fourth Amended and Restated Shareholders Agreement with certain pre-IPO stockholders, including entities affiliated with current directors, which granted certain information and participation rights (terminated upon IPO) and registration rights.
• An option agreement (September 2020) and subsequent license agreement (June 2022) with Dianthus Therapeutics Inc. for ZB005 involved reimbursement of R&D expenses ($5.1 million in 2024). This was a related party transaction as Tellus (affiliated with CEO Moulder) and Fairmount (affiliated with director Kiselak) were 5%+ stockholders of both companies. The rights were transferred to Tenacia Biotechnology in October 2024.
• Agreements with Viridian Therapeutics, Inc. (License Agreement in October 2020 for ZB001, Manufacturing Development and Supply Agreement in May 2022, and other letter agreements) are considered related party transactions because Fairmount Funds Management LLC (affiliated with director Kiselak) beneficially owns more than 5% of the company's capital stock and is a 10% or greater stockholder of Viridian.

Stakeholder Impact

• Shareholders will participate in the virtual Annual Meeting to vote on director elections and auditor ratification. Existing shareholders experienced dilution from the 2025 PIPE and 2024 Series C financing. Certain pre-IPO shareholders hold registration rights.
• Employees benefit from a 401(k) matching program and equity incentive plans designed to align their interests with long-term company performance and aid in retention.
• Directors and Executive Officers are subject to corporate governance policies, including clawback, insider trading, and anti-hedging policies. Their compensation structure includes base salary, annual cash bonuses, and long-term equity incentives.
• Regulatory Bodies: The company adheres to SEC and Nasdaq rules regarding proxy solicitations, financial reporting, and corporate governance.
• Partners (e.g., InnoCare, Zai Lab): Strategic partnerships are crucial for pipeline expansion and commercialization efforts, involving significant financial commitments and potential future milestones.

Next Steps

• Stockholders to vote on director nominees and auditor ratification at the 2026 Annual Meeting on May 11, 2026.
• The company will file a Current Report on Form 8-K with the SEC within four business days after the Annual Meeting to announce final voting results.
• The board of directors will reduce its size by one following the 2026 Annual Meeting due to Tomas Kiselak not standing for reelection.
• The company expects to generally grant stock options or other equity-based awards to executive officers each year in the second quarter.
• Non-employee director compensation cash retainers for certain committee roles will increase effective January 1, 2026.
• The company is obligated to make an additional one-time non-refundable cash payment of $25.0 million and issue an additional 2,000,000 shares of common stock to InnoCare upon the occurrence of Zenas Phase 3 clinical trial for orelabrutinib or by March 31, 2026, upon certain specified events.
• Potential future regulatory and commercial milestone payments to InnoCare of up to $723.0 million for orelabrutinib and up to $656.0 million for preclinical compounds.

Key Dates

Keywords

Zenas BioPharma, ZBIO, Proxy Statement, Annual Meeting, Corporate Governance, Director Election, Auditor Ratification, Executive Compensation, SEC Filing, Biotechnology, Life Sciences, PIPE Financing, InnoCare, Orelabrutinib, ZB021, ZB022, Stock Options, Board of Directors